NASDAQ · Biotechnology

Apnimed, Inc. (APMD) Stock

$26.31 -5.65% NASDAQ: APMD Healthcare

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.

Valuation

MetricValue
Price$26.31
Market Cap$1.05B
P/E Ratio8.69
P/B Ratio—
P/S Ratio8.79
EPS (TTM)$3.05
52-Week High$29.15
52-Week Low$16.12
Dividend Yield—

Financials & Margins

MetricValue
ROE—
ROA—
ROCE—
Gross Margin93.73%
Operating Margin80.23%
Net Margin-26.49%
Debt/Equity—
Current Ratio1.91

Latest News

Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire · Aug 3, 2026 Apnimed Announces Pricing of Upsized Initial Public Offering PR Newswire · Jul 31, 2026

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield—
Quick Ratio—
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held1.30%
Institutions Held0.00%
Institutions Float Held0.00%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Apnimed, Inc.

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Apnimed, Inc. is headquartered in US.

Apnimed, Inc. (APMD) stock trades at $26.31 with a market capitalization of $1.05B. The stock is valued at a price-to-earnings (P/E) ratio of 8.69, price-to-sales of 8.79. Over the past 52 weeks the stock has ranged between $16.12 and $29.15, and currently trades 9.7% below its 52-week high.

On profitability, Apnimed, Inc. generates an operating margin of 80.23%, a net profit margin of -26.49%.

Official website: apnimed.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides